At TAAV we produce enzymatic DNA as an alternative to plasmids DNA for the manufacture of adeno-associated virus (AAV). Our disruptive technology is creating a new industry standard for transfection-based rAAV production.
The synthetic process we use leads to high yields shortening manufacturing timelines, facilitating quicker production of rAAV and potentially increasing safety by virtually eliminating bacterial sequences that are present when using plasmid DNA.
Brands: TAAV is advancing gene therapy by offering neDNA™: an enzymatic linear, double stranded DNA as the new industry standard for transfection-based rAAV production.
.
annualmeeting.asgct.org
